[{"orgOrder":0,"company":"Cimeio Therapeutics","sponsor":"Prime Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"CD117-shielded Cell","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Cimeio Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cimeio Therapeutics \/ Cimeio Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Cimeio Therapeutics \/ Cimeio Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by Cimeio Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Under the collaboration, Prime Medicine will receive an exclusive option to license Cimeio’s cell shielding technology for CD117-shielded HSC transplant, as well as in vivo editing of CD117-shielded HSCs, for genetic diseases.

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          June 22, 2023

                          Lead Product(s) : CD117-shielded Cell,Inapplicable

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Recipient : Prime Medicine

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank